<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00866879</url>
  </required_header>
  <id_info>
    <org_study_id>STU8308 0773-017</org_study_id>
    <secondary_id>0468H1-4472</secondary_id>
    <nct_id>NCT00866879</nct_id>
  </id_info>
  <brief_title>Randomized Conversion of Calcineurin-Inhibitors in Renal Allograft Recipients</brief_title>
  <official_title>Randomized Conversion of Calcineurin-Inhibitors(Tacrolimus to Sirolimus),6-24 Months Post Transplant Prednisone-Free Immunosuppression Regimen: Impact of Incidence of Acute Cellular Rejection,Renal Allograft Function &amp; Lymphocytes Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being done to investigate the impact of changing immunosuppressive medications
      from tacrolimus (Prograf®) to sirolimus (Rapamune®) between 6 and 24 months post transplant.
      The primary purpose of this research study is to evaluate whether the use of mycophenolate
      mofetil(MMF)/Cellcept® and tacrolimus(TAC)/Prograf® (Group 1) or mycophenolate
      mofetil(MMF)/Cellcept® and sirolimus/Rapamune® (Group 2) impacts the incidence of acute
      cellular rejection in post kidney transplant patients. This study will examine whether
      switching from tacrolimus to sirolimus will better preserve long-term kidney function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For this research study, between 6 and 24 Months post-transplant, we plan to prospectively
      randomize 2:1 renal transplant patients to either:

        -  Substitute tacrolimus (TAC) with sirolimus and continue mycophenolate mofetil (MMF) or

        -  Continue with tacrolimus (TAC) and mycophenolate mofetil (MMF)

      A total of 400 patients are expected to be screened for the randomization. We expect to
      randomize 275 renal transplant patients into this protocol (275 donors to be recruited).

      The following data will be collected at the time of randomization:

      Recipient demographics: (i) age at transplantation, (ii) sex, and (iii) race.

      Clinical history: (i) causes of end-stage renal disease, and (ii) past medical history.

      Transplant related information: (i) donor age, (ii) cadaveric versus living kidney
      transplant, (iii) histocompatibility and cross match data, (iv) viral serology, (v) history
      of acute rejection and delayed graft function, (vi) use of induction therapy and
      immunosuppressants, (vii) use of ACEI and/or ARB, and (viii) level of renal allograft
      function-estimated GFR (e-GFR(12) using MDRD formula, proteinuria.

      Peripheral blood leukocytes will be obtained from renal transplant recipients for baseline
      (prior to randomization) lymphocytes functional activity and characterization of lymphocytes
      subpopulations by flow cytometry analysis.

      Peripheral donor leukocytes (from living donor patients) will also be obtained at the time of
      randomization. These donor leukocytes will be used as stimulator cells to study the
      functional activity of the recipient's lymphocytes function.

      The recipients assigned to continue with tacrolimus and MMF will be routinely followed at the
      outpatient Comprehensive Transplant Center (CTC) with monthly labs. In addition to labs at
      baseline pre-randomization, 6, 12 and 24 Months post-randomization, peripheral blood
      leukocytes will be obtained to study lymphocytes functional activity and to characterize
      lymphocytes subpopulations by flow cytometry analysis.

      Post randomization: The recipients assigned to switch from tacrolimus to sirolimus and
      continue with MMF will be routinely followed at the CTC with monthly labs. During the period
      of conversion from tacrolimus to sirolimus, weekly labs will be obtained to monitor renal
      function and bone marrow function. In addition to labs at baseline pre-randomization, 6, 12
      and 24 Months post-randomization, peripheral blood leukocytes will be obtained to study
      lymphocytes functional activity to characterize lymphocytes subpopulations by flow cytometry
      analysis. Urine will be collected to assess tubular toxicity by evaluating urinary
      biomarkers.

      Both groups of patients will be followed for 2 years post-randomization. In addition to
      monitoring renal allograft function, we will evaluate the incidence of acute rejection,
      patient and graft survival, impact of CI conversion on the lipid profile, incidence of
      hypertension, malignancies, opportunistic infections, and post-transplant diabetes mellitus
      (DM). For those willing to undergo an optional kidney biopsy, one will be performed at the
      end of the second year in order to evaluate renal allograft pathology and renal allograft
      tissue gene expression profiles of the two groups.

      With the peripheral leukocytes obtained at baseline prior to randomization and at 6, 12 and
      24 Months post-randomization, we will investigate possible modifications of lymphocytes
      function and the lymphocytes subpopulations that might have occurred as a consequence of the
      switch from tacrolimus to sirolimus.

      Obtaining renal allograft tissue samples at 24 months post randomization can have potential
      important ramifications to help explain the mechanisms of fibrosis and tubular atrophy
      typically associated with CI and the role of CI elimination with the substitution of
      sirolimus (SRL). All data will then be analyzed comparing gene expression profiles of
      peripheral blood (Pax gene tubes are routinely collected at the different time points as part
      of the original study). Based on power analysis, we will perform 24 months post randomization
      biopsies in 70% of the total subjects enrolled in the study (approximately 46 subjects from
      the tacrolimus/MMF group and approximately 93 subjects from the sirolimus/MMF group).

      We plan to obtain renal allograft biopsies at 24 Months for those that consent for this
      additional biopsy. This will be compared to the standard of care 12 months post-transplant
      biopsy to allow us to address the effect of immunosuppressive modifications on renal
      allograft pathology at 24 months post randomization. Renal allograft biopsies will also be
      stored in RNA later to further extend our knowledge on the effect of CI free
      immunosuppression on gene expression profiles.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2007</start_date>
  <completion_date type="Actual">March 2019</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Acute Cellular Rejection</measure>
    <time_frame>Assessed at 6 Months, 12 Months, 24 Months, months 24 reported</time_frame>
    <description>The primary purpose of this research study is to evaluate whether the use of mycophenolate mofetil/Cellcept ® and either tacrolimus/Prograf ® (Group #1) or mycophenolate mofetil/Cellcept ® and sirolimus/Rapamune® (Group #2) impacts the incidence of acute cellular rejection in post-kidney transplant patients. This study will examine whether switching from tacrolimus to sirolimus will better preserve long-term kidney function.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Renal Allograft Function Calculated With e-GFR and Proteinuria</measure>
    <time_frame>Assessed at 6 Months, 12 Months, 24 Months, months 24 reported</time_frame>
    <description>Evaluate whether CI conversion (tacrolimus→sirolimus) contributes positively or negatively on the renal allograft function calculated with e-GFR and proteinuria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate if CI Conversion Impacts on Lipid Profile, Incidence of Hypertension, Malignancies, and Opportunistic Infections and Post-transplant DM</measure>
    <time_frame>Assessed at 6 Months, 12 Months, 24 Months, months 24 reported</time_frame>
    <description>In addition to monitoring renal allograft function, evaluation will be conducted on the incidence of acute rejection, patient and graft survival, the impact of CI conversion on the lipid profile, the incidence of hypertension, malignancies, opportunistic infections and post-transplant DM (de novo diabetes mellitus).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient and Graft Survival</measure>
    <time_frame>Assessed at 6 Months, 12 Months, 24 Months, months 24 reported</time_frame>
    <description>This study also reviews the impact of the immunosuppressive medications on patient and graft survival.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Regulatory T Cells</measure>
    <time_frame>Assessed at 6 Months, 12 Months, 24 Months, months 24 reported</time_frame>
    <description>Specifically we reported here the percentage of regulatory T cells that were present in the two groups at 24 months post randomization.
With peripheral leukocytes taken at baseline (first visit) prior to randomization and at 6, 12 and 24 Months post-randomization, researchers will also review possible modifications of lymphocytes function and of the lymphocytes subpopulations that might have occurred as a consequence of the switch from tacrolimus to sirolimus (randomization).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">275</enrollment>
  <condition>Renal Transplant Rejection</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 1 will continue immunosuppression medication per standard of care (SOC) at Northwestern by taking mycophenolate mofetil and tacrolimus.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Transition to Sirolimus Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 2 will switch immunosuppression medication to taking mycophenolate mofetil and sirolimus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Donors</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Data and blood samples from the donors are collected in this study to contribute to the general knowledge to be used in assessing the two donor recipient groups, which are the target of this study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus</intervention_name>
    <description>Sirolimus will initially be given at a dose of 2-4 mg orally (PO) daily. The dose will be modified to achieve 24 hours trough concentrations of 6-10 ng/ml by high-performance liquid chromatography (HPLC) assay. This medication will be given in an open label fashion. The first dose of sirolimus will be given at the time of randomization to those patients assigned to have tacrolimus switched to sirolimus.</description>
    <arm_group_label>Transition to Sirolimus Group</arm_group_label>
    <other_name>Rapamune</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Demographic Data, Medical History, and Donor Data</intervention_name>
    <description>Age at transplant, sex, race, cause of end-stage renal disease, medical history, donor age, cadaveric vs. living kidney transplant, histocompatibility/cross match data, viral serology, history of acute rejection and delayed graft function, use of induction therapy and immunosuppressants, use of Angiotensin Converting Enzyme Inhibitor (ACEI) and/or Angiotensin Receptor Blockers (ARB) level of renal allograft function-estimated GFR (e-GFR(12) using Modification of Diet in Renal Disease (MDRD) formula, proteinuria.</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Transition to Sirolimus Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood Draws for Control Group</intervention_name>
    <description>Subjects maintaining standard of care drug treatment of TAC and MMF will have monthly labs in addition to the baseline pre-randomization labs, at 6, 12, and 24 Months post-randomization. Peripheral blood leukocytes will be obtained.</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood Draws for Experimental Group</intervention_name>
    <description>This group will have monthly labs taken but will also have weekly labs during the period of conversion to monitor renal function and bone marrow function. In addition to the baseline pre-randomization labs, and labs collected at 6, 12, and 24 Months post-randomization, peripheral blood leukocytes will be obtained.</description>
    <arm_group_label>Transition to Sirolimus Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Donor Blood Draws</intervention_name>
    <description>Peripheral blood leukocytes from living donors obtained at the time of randomization. These donor leukocytes will be used as stimulator cells to study the functional activity of the recipient's lymphocytes function.</description>
    <arm_group_label>Donors</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Donor Information</intervention_name>
    <description>Donor age, cadaveric vs. living donor, and histocompatibility and cross match to recipient</description>
    <arm_group_label>Donors</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Kidney Biopsy</intervention_name>
    <description>Kidney biopsy at 24 Months to compare to the standard of care biopsy taken at 12 Months. This information will help evaluate renal allograft pathology and renal allograft tissue gene expression profiles of the two groups. Renal allograft biopsies will be stored in RNA later (preservative) to further extend knowledge on the effect of calcineurin-inhibitors (CI) free immunosuppression on gene expression profiles.</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Transition to Sirolimus Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects should be adults ≥ 18- ≤ 70 years of age

          2. Subjects can be either gender or of any ethnic background

          3. Subjects should be single organ recipients (kidney only)

          4. Subjects must be able to understand the protocol and provide informed consent.

        Exclusion Criteria:

          1. Subjects with end-stage renal disease (ESRD) secondary to primary focal segmental
             glomerulonephritis (FSGS).

          2. Inability to comply with study procedures

          3. Inability to sign the informed consent

          4. Subjects with a significant or active infection

          5. Subjects who are pregnant or nursing females

          6. Subjects with a history of severe hyperlipidemia not controlled with statins, patients
             with at total cholesterol of &gt; 400 mg/dl

          7. Subjects with a platelet count &lt;100,000mm3 white blood cell (WBC)&lt; 2,000mm3

          8. Subjects with severe proteinuria at the time of randomization (&gt;2gm/day)

          9. Subjects with more then 2 episodes of acute cellular rejection post transplantation
             will be excluded from this study

         10. An estimated GFR&lt;40 cc/min

         11. A history of malignancy during the post-transplant period (other than treated basal
             cell cancer and/or squamous cell cancer)

         12. Subjects, who, due to the existence of a surgical, medical or psychiatric condition,
             other than the current transplant, which in the opinion of the investigator, precludes
             enrollment into this trial

         13. A history of albumin-creatinine ratio (ACR) during the most recent previous 3 months
             prior to randomization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lorenzo Gallon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern Univesity, Northwestern Memorial Hospital, Northwestern Medical Faculty Foundation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Ojo AO, Held PJ, Port FK, Wolfe RA, Leichtman AB, Young EW, Arndorfer J, Christensen L, Merion RM. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med. 2003 Sep 4;349(10):931-40.</citation>
    <PMID>12954741</PMID>
  </reference>
  <reference>
    <citation>Stoves J, Lindley EJ, Barnfield MC, Burniston MT, Newstead CG. MDRD equation estimates of glomerular filtration rate in potential living kidney donors and renal transplant recipients with impaired graft function. Nephrol Dial Transplant. 2002 Nov;17(11):2036-7.</citation>
    <PMID>12401874</PMID>
  </reference>
  <reference>
    <citation>Gonwa TA, Mai ML, Melton LB, Hays SR, Goldstein RM, Levy MF, Klintmalm GB. End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment. Transplantation. 2001 Dec 27;72(12):1934-9.</citation>
    <PMID>11773892</PMID>
  </reference>
  <reference>
    <citation>Fisher NC, Nightingale PG, Gunson BK, Lipkin GW, Neuberger JM. Chronic renal failure following liver transplantation: a retrospective analysis. Transplantation. 1998 Jul 15;66(1):59-66.</citation>
    <PMID>9679823</PMID>
  </reference>
  <reference>
    <citation>Hornberger J, Best J, Geppert J, McClellan M. Risks and costs of end-stage renal disease after heart transplantation. Transplantation. 1998 Dec 27;66(12):1763-70.</citation>
    <PMID>9884274</PMID>
  </reference>
  <reference>
    <citation>Goldstein DJ, Zuech N, Sehgal V, Weinberg AD, Drusin R, Cohen D. Cyclosporine-associated end-stage nephropathy after cardiac transplantation: incidence and progression. Transplantation. 1997 Mar 15;63(5):664-8.</citation>
    <PMID>9075835</PMID>
  </reference>
  <reference>
    <citation>Myers BD, Ross J, Newton L, Luetscher J, Perlroth M. Cyclosporine-associated chronic nephropathy. N Engl J Med. 1984 Sep 13;311(11):699-705.</citation>
    <PMID>6382005</PMID>
  </reference>
  <reference>
    <citation>Bennett WM, DeMattos A, Meyer MM, Andoh T, Barry JM. Chronic cyclosporine nephropathy: the Achilles' heel of immunosuppressive therapy. Kidney Int. 1996 Oct;50(4):1089-100. Review.</citation>
    <PMID>8887265</PMID>
  </reference>
  <reference>
    <citation>Bennett WM. Insights into chronic cyclosporine nephrotoxicity. Int J Clin Pharmacol Ther. 1996 Nov;34(11):515-9. Review.</citation>
    <PMID>8937936</PMID>
  </reference>
  <reference>
    <citation>Myers BD. Cyclosporine nephrotoxicity. Kidney Int. 1986 Dec;30(6):964-74. Review.</citation>
    <PMID>3546916</PMID>
  </reference>
  <reference>
    <citation>Puschett JB, Greenberg A, Holley J, McCauley J. The spectrum of ciclosporin nephrotoxicity. Am J Nephrol. 1990;10(4):296-309. Review.</citation>
    <PMID>2240057</PMID>
  </reference>
  <reference>
    <citation>Young EW, Ellis CN, Messana JM, Johnson KJ, Leichtman AB, Mihatsch MJ, Hamilton TA, Groisser DS, Fradin MS, Voorhees JJ. A prospective study of renal structure and function in psoriasis patients treated with cyclosporin. Kidney Int. 1994 Oct;46(4):1216-22.</citation>
    <PMID>7861719</PMID>
  </reference>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>March 19, 2009</study_first_submitted>
  <study_first_submitted_qc>March 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 23, 2009</study_first_posted>
  <results_first_submitted>April 9, 2019</results_first_submitted>
  <results_first_submitted_qc>May 8, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 31, 2019</results_first_posted>
  <last_update_submitted>June 18, 2019</last_update_submitted>
  <last_update_submitted_qc>June 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Lorenzo Gallon</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Sirolimus</keyword>
  <keyword>Rapamune</keyword>
  <keyword>Immunosuppression</keyword>
  <keyword>Renal allograft function</keyword>
  <keyword>Lymphocytes function</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 1, 2012</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/79/NCT00866879/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Donor participants were no part of our outcome analysis because their participation was only on the basis of providing blood for testing the immune system of the recipients.
The analysis of the recipients was intention to treat therefore all recipient participants completed the study period</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Control</title>
          <description>Group 1 will continue immunosuppression medication per standard of care (SOC) at Northwestern by taking mycophenolate mofetil and tacrolimus.</description>
        </group>
        <group group_id="P2">
          <title>Transition to Sirolimus Group</title>
          <description>Group 2 will switch immunosuppression medication to taking mycophenolate mofetil and sirolimus</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="90"/>
                <participants group_id="P2" count="185"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="90"/>
                <participants group_id="P2" count="185"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Donor participants were no part of our outcome analysis because their participation was only on the basis of providing blood for testing the immune system of the recipients.
The analysis of the recipients was intention to treat therefore all recipient participants completed the study period</population>
      <group_list>
        <group group_id="B1">
          <title>Control</title>
          <description>Group 1 will continue immunosuppression medication per standard of care (SOC) at Northwestern by taking mycophenolate mofetil and tacrolimus.</description>
        </group>
        <group group_id="B2">
          <title>Transition to Sirolimus Group</title>
          <description>Group 2 will switch immunosuppression medication to taking mycophenolate mofetil and sirolimus</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="90"/>
            <count group_id="B2" value="185"/>
            <count group_id="B3" value="275"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Age in years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.2" spread="12.6"/>
                    <measurement group_id="B2" value="38.8" spread="12.5"/>
                    <measurement group_id="B3" value="38.9" spread="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Sex male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="106"/>
                    <measurement group_id="B3" value="161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sex female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>white</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="83"/>
                    <measurement group_id="B3" value="127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="185"/>
                    <measurement group_id="B3" value="275"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HLA mismatch</title>
          <description>The number of human leukocyte antigens (HLAs) found on the cells of a donor organ but not found on the cells of the organ recipient</description>
          <units>HLA antigens</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.9" spread="1.7"/>
                    <measurement group_id="B2" value="3.61" spread="1.82"/>
                    <measurement group_id="B3" value="3.8" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Donor type</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Living donors</title>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="130"/>
                    <measurement group_id="B3" value="193"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Cadaveric kidneys</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>PRA &gt;20%</title>
          <description>A panel-reactive antibody (PRA) is a group of antibodies in a test serum that are reactive against any of several known specific antigens in a panel of test cells or purified HLA antigens from cells. A panel-reactive antibody test (PRA test) is an immunologic test routinely performed by clinical laboratories on the blood of people awaiting organ transplantation.
This result is the number of participants on the study that had PRA &gt; 20% at the time of Transplantation</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetis mellitus</title>
          <description>Number of participants that were diagnosed with Diabetes at the time of Transplantation</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Elevated blood pressure</title>
          <description>Number of participant with elevated blood pressure at the time of Transplantation</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="158"/>
                    <measurement group_id="B3" value="234"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Coronary artery disease (CAD)</title>
          <description>Coronary artery disease (CAD) occurs when the arteries that supply blood to the heart become hardened and narrowed due to the buildup of cholesterol and other substances, known as plaque</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Acute Cellular Rejection</title>
        <description>The primary purpose of this research study is to evaluate whether the use of mycophenolate mofetil/Cellcept ® and either tacrolimus/Prograf ® (Group #1) or mycophenolate mofetil/Cellcept ® and sirolimus/Rapamune® (Group #2) impacts the incidence of acute cellular rejection in post-kidney transplant patients. This study will examine whether switching from tacrolimus to sirolimus will better preserve long-term kidney function.</description>
        <time_frame>Assessed at 6 Months, 12 Months, 24 Months, months 24 reported</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Group 1 will continue immunosuppression medication per standard of care (SOC) at Northwestern by taking mycophenolate mofetil and tacrolimus.</description>
          </group>
          <group group_id="O2">
            <title>Transition to Sirolimus Group</title>
            <description>Group 2 will switch immunosuppression medication to taking mycophenolate mofetil and sirolimus</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Acute Cellular Rejection</title>
          <description>The primary purpose of this research study is to evaluate whether the use of mycophenolate mofetil/Cellcept ® and either tacrolimus/Prograf ® (Group #1) or mycophenolate mofetil/Cellcept ® and sirolimus/Rapamune® (Group #2) impacts the incidence of acute cellular rejection in post-kidney transplant patients. This study will examine whether switching from tacrolimus to sirolimus will better preserve long-term kidney function.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="185"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Renal Allograft Function Calculated With e-GFR and Proteinuria</title>
        <description>Evaluate whether CI conversion (tacrolimus→sirolimus) contributes positively or negatively on the renal allograft function calculated with e-GFR and proteinuria</description>
        <time_frame>Assessed at 6 Months, 12 Months, 24 Months, months 24 reported</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Group 1 will continue immunosuppression medication per standard of care (SOC) at Northwestern by taking mycophenolate mofetil and tacrolimus.</description>
          </group>
          <group group_id="O2">
            <title>Transition to Sirolimus Group</title>
            <description>Group 2 will switch immunosuppression medication to taking mycophenolate mofetil and sirolimus</description>
          </group>
        </group_list>
        <measure>
          <title>Renal Allograft Function Calculated With e-GFR and Proteinuria</title>
          <description>Evaluate whether CI conversion (tacrolimus→sirolimus) contributes positively or negatively on the renal allograft function calculated with e-GFR and proteinuria</description>
          <units>mL/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="185"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.6" spread="20.4"/>
                    <measurement group_id="O2" value="58.4" spread="25.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluate if CI Conversion Impacts on Lipid Profile, Incidence of Hypertension, Malignancies, and Opportunistic Infections and Post-transplant DM</title>
        <description>In addition to monitoring renal allograft function, evaluation will be conducted on the incidence of acute rejection, patient and graft survival, the impact of CI conversion on the lipid profile, the incidence of hypertension, malignancies, opportunistic infections and post-transplant DM (de novo diabetes mellitus).</description>
        <time_frame>Assessed at 6 Months, 12 Months, 24 Months, months 24 reported</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Group 1 will continue immunosuppression medication per standard of care (SOC) at Northwestern by taking mycophenolate mofetil and tacrolimus.</description>
          </group>
          <group group_id="O2">
            <title>Transition to Sirolimus Group</title>
            <description>Group 2 will switch immunosuppression medication to taking mycophenolate mofetil and sirolimus</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluate if CI Conversion Impacts on Lipid Profile, Incidence of Hypertension, Malignancies, and Opportunistic Infections and Post-transplant DM</title>
          <description>In addition to monitoring renal allograft function, evaluation will be conducted on the incidence of acute rejection, patient and graft survival, the impact of CI conversion on the lipid profile, the incidence of hypertension, malignancies, opportunistic infections and post-transplant DM (de novo diabetes mellitus).</description>
          <units>number of incidents</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="185"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Infections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malignancies</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Proteinura</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyperlipidemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NODAT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BK viremia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BK nephropathy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutropenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient and Graft Survival</title>
        <description>This study also reviews the impact of the immunosuppressive medications on patient and graft survival.</description>
        <time_frame>Assessed at 6 Months, 12 Months, 24 Months, months 24 reported</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Group 1 will continue immunosuppression medication per standard of care (SOC) at Northwestern by taking mycophenolate mofetil and tacrolimus.</description>
          </group>
          <group group_id="O2">
            <title>Transition to Sirolimus Group</title>
            <description>Group 2 will switch immunosuppression medication to taking mycophenolate mofetil and sirolimus</description>
          </group>
        </group_list>
        <measure>
          <title>Patient and Graft Survival</title>
          <description>This study also reviews the impact of the immunosuppressive medications on patient and graft survival.</description>
          <units>number of incidents</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="185"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Kidney transplant loss</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Regulatory T Cells</title>
        <description>Specifically we reported here the percentage of regulatory T cells that were present in the two groups at 24 months post randomization.
With peripheral leukocytes taken at baseline (first visit) prior to randomization and at 6, 12 and 24 Months post-randomization, researchers will also review possible modifications of lymphocytes function and of the lymphocytes subpopulations that might have occurred as a consequence of the switch from tacrolimus to sirolimus (randomization).</description>
        <time_frame>Assessed at 6 Months, 12 Months, 24 Months, months 24 reported</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Group 1 will continue immunosuppression medication per standard of care (SOC) at Northwestern by taking mycophenolate mofetil and tacrolimus.</description>
          </group>
          <group group_id="O2">
            <title>Transition to Sirolimus Group</title>
            <description>Group 2 will switch immunosuppression medication to taking mycophenolate mofetil and sirolimus</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Regulatory T Cells</title>
          <description>Specifically we reported here the percentage of regulatory T cells that were present in the two groups at 24 months post randomization.
With peripheral leukocytes taken at baseline (first visit) prior to randomization and at 6, 12 and 24 Months post-randomization, researchers will also review possible modifications of lymphocytes function and of the lymphocytes subpopulations that might have occurred as a consequence of the switch from tacrolimus to sirolimus (randomization).</description>
          <units>% of Treg Cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="185"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75" spread="7.1"/>
                    <measurement group_id="O2" value="98" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 months</time_frame>
      <desc>Donor participants were no part of our outcome analysis because their participation was only on the basis of providing blood for testing the immune system of the recipients.
The analysis of the recipients was intention to treat therefore all recipient participants completed the study period</desc>
      <group_list>
        <group group_id="E1">
          <title>Control</title>
          <description>Group 1 will continue immunosuppression medication per standard of care (SOC) at Northwestern by taking mycophenolate mofetil and tacrolimus. Patients were followed for 24 months post randomization</description>
        </group>
        <group group_id="E2">
          <title>Transition to Sirolimus</title>
          <description>Group 2 will switch immunosuppression medication to taking mycophenolate mofetil and sirolimus. Patients were followed for 24 months post randomization</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="117" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="90"/>
                <counts group_id="E2" events="35" subjects_affected="35" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Malignancies</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="90"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal allograft loss</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="90"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="90"/>
                <counts group_id="E2" events="61" subjects_affected="61" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="135" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperlipidemia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="90"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="90"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections</sub_title>
                <counts group_id="E1" events="33" subjects_affected="33" subjects_at_risk="90"/>
                <counts group_id="E2" events="83" subjects_affected="83" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>BK viremia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="90"/>
                <counts group_id="E2" events="28" subjects_affected="28" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>BK nephropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Lorenzo Gallon, MD</name_or_title>
      <organization>Northwestern University</organization>
      <phone>3126954457</phone>
      <email>l-gallon@northwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

